Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle.
The invasion status of tumour-draining lymph nodes (LNs) is a critical indicator of cancer stage and is important for treatment planning. Clinicians currently use planar scintigraphy and single-photon emission computed tomography (SPECT) with (99m)Tc-radiocolloid to guide biopsy and resection of LNs. However, emerging multimodality approaches such as positron emission tomography combined with magnetic resonance imaging (PET/MRI) detect sites of disease with higher sensitivity and accuracy. Here we present a multimodal nanoparticle, (89)Zr-ferumoxytol, for the enhanced detection of LNs with PET/MRI. For genuine translational potential, we leverage a clinical iron oxide formulation, altered with minimal modification for radiolabelling. Axillary drainage in naive mice and from healthy and tumour-bearing prostates was investigated. We demonstrate that (89)Zr-ferumoxytol can be used for high-resolution tomographic studies of lymphatic drainage in preclinical disease models. This nanoparticle platform has significant translational potential to improve preoperative planning for nodal resection and tumour staging.
1] Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Sciences, The Johns Hopkins School of Medicine, 601 N. Caroline Street, JHOC 3223, Baltimore, Maryland 21287, USA [2] Department of Radiology, Memorial Sloan-Kettering Cancer Center (MSKCC), 1275 York Street, Box 248, New York, New York 10065, USA.
Daniel L J
DL
Thorek
1] Department of Surgery, Memorial Sloan-Kettering Cancer Center (MSKCC), 1275 York Street, Box 248, New York, New York 10065, USA [2] Department of Urology, Lund University, Skåne University Hospital, SE-205 02 Malmö, Sweden.
David
D
Ulmert
Department of Biomedical Engineering, The City College of New York, ST-401, 160 Convent Avenue, New York, New York 10031, USA.
Ndeye-Fatou M
NF
Diop
Department of Medical Physics, Memorial Sloan-Kettering Cancer Center (MSKCC), 1275 York Street, Box 248, New York, New York 10065, USA.
Mihaela E
ME
Lupu
Department of Radiology, Memorial Sloan-Kettering Cancer Center (MSKCC), 1275 York Street, Box 248, New York, New York 10065, USA.
Michael G
MG
Doran
Department of Radiology, Memorial Sloan-Kettering Cancer Center (MSKCC), 1275 York Street, Box 248, New York, New York 10065, USA.
Ruimin
R
Huang
Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Sciences, The Johns Hopkins School of Medicine, 601 N. Caroline Street, JHOC 3223, Baltimore, Maryland 21287, USA.
Diane S
DS
Abou
1] Department of Radiology, Memorial Sloan-Kettering Cancer Center (MSKCC), 1275 York Street, Box 248, New York, New York 10065, USA [2] Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center (MSKCC), 1275 York Street, Box 248, New York, New York 10065, USA.
Steven M
SM
Larson
1] Department of Radiology, Memorial Sloan-Kettering Cancer Center (MSKCC), 1275 York Street, Box 248, New York, New York 10065, USA [2] Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center (MSKCC), 1275 York Street, Box 248, New York, New York 10065, USA.
Jan
J
Grimm
D000818:Animals; D004195:Disease Models, Animal; D004322:Drainage; D052203:Ferrosoferric Oxide / Q000008:administration & dosage; D005818:Genetic Engineering; D008198:Lymph Nodes / Q000000981:diagnostic imaging* / Q000601:surgery; D008279:Magnetic Resonance Imaging; D008297:Male; D008822:Mice, Transgenic; D064847:Multimodal Imaging; D053758:Nanoparticles / Q000008:administration & dosage; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging
D052203:Ferrosoferric Oxide